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Beckwith–Wiedemann syndrome (BWS) is a model human imprinting disorder resulting from altered activity of one or more genes in the
11p15.5 imprinted gene cluster. Approximately 20% of BWS cases have uniparental disomy (UPD) of chromosome 11. Such cases appear to
result from mitotic recombination occurring in early embryogenesis and offer a rare opportunity to study mitotic recombination in nonneoplastic
cells. We analyzed a cohort of 52 children with BWS and UPD using a panel of microsatellite markers for chromosome 11. All cases demonstrated
mosaic paternal isodisomy, and IGF2 and H19 were included in the segment of UPD in all cases. However, the extent of segmental disomy was
variable, with no evidence of clustering of the proximal UPD breakpoint. In most cases (92% of those informative) UPD did not involve 11q, but 4
patients demonstrated UPD for the whole of chromosome 11. In contrast to meiotic recombination, the mitotic recombination frequency did not
decline near the centromere.
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site for meiosis I to occur, and the mechanisms and the
consequences of meiotic recombination have been studied
extensively (reviewed in [1]). Although mitotic recombination
has received less attention, this process occurs frequently in
humans and the resulting loss of heterozygosity is an important
mechanism of tumor-suppressor inactivation in many human
cancers [2–4]. The increasing application of genome-wide
genotyping (e.g., SNP microarrays) and copy number analysis
techniques (e.g., array CGH) has highlighted the importance of
mitotic recombination in tumorigenesis [5–7]. Hence there is
relatively little information available on mitotic recombination
events in nonneoplastic cells, although human disease may
result from mitotic recombination affecting imprinted gene
regions. Thus mitotic recombination may generate loss of
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doi:10.1016/j.ygeno.2007.01.005disomy (UPD). Mosaic paternal UPD is classically seen in
Beckwith–Wiedemann syndrome (BWS), a model imprinting
disorder characterized by pre- and postnatal overgrowth,
developmental defects, and susceptibility to embryonal tumors
[8,9]. About 20% of sporadic BWS cases have segmental
uniparental disomy involving the imprinted gene cluster at
11p15.5 [10,11]. While the frequency and phenotype of UPD
are well established, the extent to which different regions on
chromosome 11 exhibit UPD has not been analyzed in detail. To
determine this information and to compare meiotic and mitotic
recombination patterns on chromosome 11, we mapped the
extent of segmental UPD in 52 children with BWS and UPD.
Results
Clinical features of the patient cohort of children with BWS
have been reported previously [12]. While the extent of
segmental disomy and proportion of cells with UPD was
variable (Fig. 1), in all cases UPD was paternal isodisomy. Four
of 52 (8%) patients studied exhibited UPD extending onto the q
arm of chromosome 11, and in all of these patients UPD was
Fig. 1. The extent of uniparental disomy along chromosome 11 in a group of
patients with BWS known to be due to paternal UPD 11p15.5. The markers
spanning the BWS critical region are shaded in gray. Black boxes represent
regions of allelic imbalance in favor of the paternal allele. Markers that were
uninformative or for which no information was available are shaded gray, and
regions for which no allelic imbalance was observed are white. All patients
continued with the status depicted at D11S2365 for the rest of the q arm except
patients 33, 42, 43, 44, 45 (UPD could be excluded at and beyond D11S4459),
34, 46, 47 (UPD could be excluded at and beyond D11S2363), and 48 (UPD
could be excluded at and beyond D11S2006). “Tumour” column: WT, Wilms
tumor; HB, hepatoblastoma.
Fig. 2. Graph to compare the rate of mitotic and meiotic recombination across
the p arm of chromosome 11. The number of UPD cases known to have not
recombined is expressed as the proportion of the total number of BWS cases
with a breakpoint on 11p (cases uninformative for that marker are excluded).
The meiotic recombination data refer to the 45 female and 40 male CEPH
probands known to have a recombination event on 11p.
Table 1
The extent of disomy in the two patients with the smallest regions of UPD
Black boxes represent regions of allelic imbalance in favor of the paternal allele.
Areas where UPD could not be proven or excluded are shaded gray, and regions
for which no allelic imbalance was observed are white. LOM, loss of maternal
methylation; NI, not informative for that marker.
614 W.N. Cooper et al. / Genomics 89 (2007) 613–617observed for all informative markers tested (covering >98% of
chromosome 11). In 2 cases it was not possible to demonstrate
or exclude UPD extending onto the q arm. Of the remaining 46
patients in which the region of UPD did not extend to 11q and in
which the breakpoint was mapped on the p arm, 14 were
proximal to D11S1981 (17.0 Mb, 21.47 cM), 15 mapped
between D11S1981 (17.0 Mb, 21.47 cM) and D11S1993(43.6 Mb, 54.09 cM), and 19 mapped between D11S1392
(34.6 Mb, 43.16 cM) and D11S2006 (59.5 Mb, 59.24 cM) (see
Fig. 1). Comparison of the centromeric mitotic recombination
breakpoint (proximal extent of disomy) to the physical distance
and meiotic recombination map (Fig. 2) did not provide strong
evidence for mitotic recombination hot spots; however, there
was possibly a slight increase in the recombination rate at the
centromere.
Two patients did not exhibit UPD at D11S1923 (3.19 Mb,
8.64 cM); patient 1 demonstrated biallelic inheritance and
patient 2 was uninformative at D11S1923 (Table 1); this marker
maps adjacent to CARS, which is thought to delineate the
centromeric end of the imprinting cluster. Therefore, the extent
of UPD in these patients was mapped more finely. Patient 2
615W.N. Cooper et al. / Genomics 89 (2007) 613–617exhibited UPD at D11S4088 (2.71 Mb, 7.03 cM); patient 1 was
uninformative at this marker, but exhibited UPD for novel
microsatellites located at 2.35 and 2.42 Mb. The imprinted
region at 11p15.5 includes regions that are differentially
methylated between the parental genomes. The H19 differen-
tially methylated region (DMR; located at 1.98 Mb) is
paternally methylated and in the methylated state is proposed
to promote the expression of IGF2 [13]. The maternally
methylated region KvDMR1 is proposed to induce CDKN1C
expression in the methylated state [14]. KvDMR1 is located at
2.68 Mb and the methylation status of this region in patient 1
was consistent with UPD, thus mapping the centromeric
recombination breakpoint in patient 1 between 2.68 and
3.19 Mb and between 2.7 and 3.70 Mb (D11S4146) in patient
2. All cases demonstrated UPD for the most telomeric markers
for which they were informative, suggesting that the telomeric
UPD boundary was less than 0.24 Mb from the telomere.
Discussion
Mitotic recombination (and consequent loss of allelic
heterozygosity (LOH)) can be a frequent cause of tumor
suppressor gene inactivation in cancer, but BWS patients with
UPD provide a rare opportunity to investigate human mitotic
recombination in nonneoplastic cells. There is relatively little
information on nonneoplastic somatic loss of heterozygosity but
a high frequency of LOH in normal T lymphocytes was
attributed primarily to mitotic recombination [4]. Interestingly it
has been suggested that the frequency of mitotic recombination
may be increased at telomeric regions but the hot spots for
meiotic and mitotic recombination may not coincide [15,16].
Paternal UPD for 11p15 accounts for approximately 20% of
sporadic BWS cases [10,11]. The 11p15.5 imprinted gene
cluster contains many genes [17], and those thought to be most
important in the pathogenesis of BWS include CDKN1C, IGF2,
and H19. The region of paternal UPD invariably includes the
imprinted gene cluster at 11p15.5; however, the extent of
isodisomy along chromosome 11 is variable [18,19]. We found
mosaic paternal isodisomy, consistent with previous reports.
Thus UPD appears to have arisen as a postzygotic event due to
mitotic recombination in early embryogenesis. Consistent with
the mosaicism, hemihypertrophy demonstrates a strong associa-
tion with UPD in BWS [12,20,21] and in some cases isodisomy
is detectable in only a subset of tissues tested [22]. This
mechanism of UPD in BWS differs from that seen in Prader–
Willi and Angelman syndromes, in which maternal hetero-
disomy and complete paternal isodisomy, respectively, occur
either as a result of nondisjunction errors during meiosis [23–
25] or, more frequently, as a result of postzygotic nondisjunc-
tion events in the early embryo [26]. It is interesting that we did
not find any evidence of nonmosaic paternal isodisomy (as seen
for chromosome 15 in Angelman syndrome) in BWS, but we
did identify four individuals with mosaic UPD for the whole of
chromosome 11. A single similar case has been reported
previously [18], suggesting that in BWS UPD is most
frequently due to mitotic recombination in the early embryo
and less commonly due to nondisjunction in the early embryo.A possible explanation for the absence of nonmosaic chromo-
some 11 paternal isodisomy is that a lack of one or more
chromosome 11 maternally expressed genes may lead to
embryonic lethality.
The level of UPD mosaicism was variable, with the ratio of
paternal to maternal alleles in blood varying between 1.4:1 and
11.3:1; however, we did not have access to the various tissue
samples that would be required for a comprehensive study of
mosaicism. Identification of tissues with the highest levels of
mosaicism might allow more detailed mapping of UPD using
SNP microarrays. Postzygotic mitotic recombination followed
by uneven distribution of chromatids to daughter cells would
produce a mixed population of normal cells, cells with maternal
UPD, and cells with paternal UPD. However, analysis of single
cells from BWS UPD patients detected only two cell
populations, normal and paternal UPD11 [27]. This suggests
that cells with paternal UPD11 may have a selective growth
advantage and that maternal UPD cells die or partition to
different parts of the conceptus.
Genomic instability is frequent in many human cancers and
may predispose to mitotic recombination. Individuals with
Bloom syndrome have an elevated frequency of sister
chromatid exchanges due to a mutation in BLM, which encodes
a RecQ helicase that is required for suppressing crossing over
during homologous recombination [28,29]. However, there is
no evidence to suggest underlying genomic instability in BWS
and so individuals with BWS and UPD provide an opportunity
to investigate mitotic recombination events in “normal cells.”
Genome-wide meiotic recombination rates vary markedly,
although recombination is usually more frequent in telomeric
regions than in centromeric regions. In addition, meiotic
recombination rates at a specific locus may vary between
sexes. High-resolution sperm-mapping studies can delineate the
presence and nature of male meiotic recombination hot spots
[30], but at much lower resolution mapping (while we
considered higher density mapping by microarray, we were
concerned that the mosaic nature of the samples would make
interpretation difficult) we did not identify regions of mitotic
recombination clustering, suggesting that the mechanisms of
meiotic and mitotic recombination may differ. In addition we
did not identify a common breakpoint region at the chromosome
11q23.3 fragile sites. However, we did observe that 13 of the 48
(27%) individuals with a mapped breakpoint transferred from
uniparental to biparental inheritance between D11S1993
(43.57 Mb) and D11S2006 (59.48 Mb). This is interesting as
the centromere is located at 51.5–54.5 Mb and meiotic
recombination is reduced in the pericentromeric region.
Mouse models of BWS may result from overexpression of
Igf2 transgenes or cdkn1c deletion, and BWS children with
paternal duplication of 11p15.5 (causing increased IGF2
expression but no effect on CDKN1C) and others with a
germ-line maternal allele CDKN1C mutation implicate IGF2
overexpression and/or CDKN1C inactivation in the pathogen-
esis of BWS. The majority of BWS children with UPD have
paternal disomy for both IGF2 and CDKN1C and while all of
our cases included the H19 differentially methylated region
(DMR1, imprinting center 1) and the IGF2 gene (thus predic-
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two cases in which it was not possible to tell from microsatellite
markers whether CDKN1C was included in the region of UPD.
However, in both cases there was loss of maternal allele
methylation at KvDMR1 (presumably due to paternal iso-
disomy). As loss of KvDMR1 methylation is associated with
reduced expression of CDKN1C, we would predict that in these
cases there would be reduced CDKN1C expression—even if
CDKN1C itself mapped outside the region of UPD. Thus it
would seem that for BWS cases with UPD, altered expression of
IGF2, H19, and CDKN1C is the rule.
Previously we reported that UPD cases with Wilms tumor
were more likely to have UPD for the 11p13 WT1Wilms tumor
suppressor gene locus than those without Wilms tumor [12].
Although the difference did not reach statistical significance,
this observation was interesting, as some evidence for
imprinting at the WT1 locus had been described. Thus Wilms
tumors with 11p13 allele loss appear to display preferential
maternal allele loss [31] and analysis of WT1 RNA shows that
there is variable biallelic expression or partial or complete
maternal repression [32–34]. In addition it has been suggested
that an alternative WT1 transcript (AWT1) and the antisense
WT1 transcript (WT1-AS, which overlaps the 5′ end of WT1)
may be imprinted [35–37]. These transcripts have a differen-
tially methylated “promoter” and are differentially expressed. It
has been shown that WT1-AS transcription can elevate WT1
protein levels in vitro [36], such that in fetal tissues both alleles
are unmethylated and transcription occurs from both alleles;
however, in adult tissues the maternal allele has been silenced
by methylation, whereas in Wilms tumors without 11p13 LOH
the fetal state is retained. Paternal UPD for 11p13 would also
have the effect of maintaining the chromosome in the fetal state
of biallelic expression of WT1-AS.
Individuals with BWS and UPD represent a valuable
resource for the study of mitotic recombination because of
the well-defined phenotype, and the subtelomeric location of
the 11p15 gene cluster. Thus there is little or no variability
in the location of the distal breakpoint, but the proximal
breakpoint is very variable. Advances in SNP microarray
technology that allow the reliable mapping of mosaic UPD
will facilitate the mapping of chromosome 11 disomy in
BWS and, for comparison, in human neoplasia [5,6].Methods
Patients were ascertained via a national research study or following referral
to the West Midlands Regional Genetics Service for diagnostic testing. Clinical
information was collected by a standard questionnaire, inspection of hospital
notes, or direct examination. Patients were included in the study following a
molecular diagnosis of BWS with UPD irrespective of the original indication for
referral.
Samples were obtained from the proband and both parents; DNA was
extracted from peripheral blood lymphocytes or tissue samples by standard
procedures.
PCR was performed on 20 ng of genomic DNA in a 10-μl total reaction
volume containing fluorescently labeled forward primer (0.2 μM), unlabeled
reverse primer (0.2 μM), dNTP (0.2 mM) ABGene Taq (0.5 U) in 1× ABGene
buffer containing 1.5 mM MgCl2. After an initial denaturation step (3 min at
96°C), 26 cycles of amplification were performed (96°C for 30 s, 55°C for 30 s,72°C for 30 s) followed by a final extension for 10 min at 72°C. The primer
sequences used were those of the Research Genetics microsatellite panel except
for novel markers generated telomeric to KvDMR1. The primers designed to
amplify the dinucleotide repeat located at 2.35 Mb had the sequences forward,
5′-AACCAGTACTGCTATGAACA, and reverse, 5′-AATAGTGCAGCCA-
CTTCGGA, and those designed to amplify the repeat at 2.42 Mb had the
sequences forward, 5′-TAGCTGAGGAGTCTATGCTA, and reverse. 5′-
GAGACAATCACAATGTCCTT.
Alleles were resolved through a 6% polyacrylamide gel on an ABI 377, and
the ratio of paternal to maternal allele intensity was determined using the
Genotyper software (ABI); a ratio of greater than 1.3:1 in favor of the paternal
allele indicated UPD.
Methylation analysis was performed following bisulfite conversion of
unmethylated cytosines to uracil. DNAwas modified [38] and then amplified by
PCR using a fluorescently labeled forward primer; for KvDMR1 methylation
analysis the primers used wereW2, 5′-GTTATTTTATATTTAGTTAGTGT-
TTTATG, and W4, 5′-TCTTACTAAAAAACTCCCTAAAAATC, as described
in [12]. The PCR products were then digested with the restriction enzyme
BstUI, which has the recognition site CGCG and hence will cut only
modified DNA derived from previously methylated DNA. The fragments
were separated on an ABI 377 and the ratio of methylated to unmethylated
DNA was determined.
The genetic distances are according to the Marshfield map [39] except for
D11S2071, D11S2365, and D11S4463, which were not mapped by Marshfield.
The physical distances are those of NCBI build 35 released May 2004.
The CEPH genotype data were obtained from http://www.cephb.fr/cephdb/.
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